August 2026– date –
-
Oral GLP-1 Drugs May Quash Brain’s Food Craving Circuit, NIH-Funded Study Suggests Role in Hedonic Eating and Addiction
ScienceDaily USA Overview A study funded by the NIH suggests that newer oral small-molecule GLP-1 drugs, such as orforglipron and danuglipron, may reduce hedonic feeding (eating for pleasure) by affecting a reward circuit in the brain. T... -
Daiichi Sankyo & AstraZeneca’s Datroway Approved in EU as Only TROP2-Directed Medicine with Overall Survival Benefit for 1st-Line Metastatic TNBC Patients Ineligible for Immunotherapy
Business Wire USA Overview Datroway, a TROP2-directed antibody-drug conjugate (ADC) by Daiichi Sankyo and AstraZeneca, received EU approval for first-line treatment of metastatic triple-negative breast cancer (TNBC) patients not eligible... -
Allogene Therapeutics’ Off-the-Shelf CAR T Cema-Cel Receives FDA RMAT & Fast Track Designations for First-Line MRD-Positive LBCL, Achieves 58.3% MRD-Negativity in Phase 2 Interim Analysis
Allogene Therapeutics Press Release USA Overview Allogene Therapeutics announced that cemacabtagene ansegedleucel (cema-cel), an off-the-shelf anti-CD19 CAR T-cell therapy, received both Regenerative Medicine Advanced Therapy (RMAT) and ... -
Henlius Initiates First-in-Human Dosing for STEAP1×CD3×CD28 Trispecific TCE HLX3902 in Metastatic Castration-Resistant Prostate Cancer and Advanced Solid Tumors
Henlius Biotech Press Release China Overview Shanghai Henlius Biotech announced the first patient dosing in a first-in-human (FIH) study for HLX3902, a trispecific T-cell engager (TCE) targeting STEAP1×CD3×CD28. This innovative trispecif... -
2026 RNA Therapeutics Transformation: FDA Approves ASO Olezarsen, siRNA Fitusiran & Plozasiran, Ushering in Diverse Nucleic Acid Era
MiraScope Unknown Overview The year 2026 marks a significant transformation in RNA therapeutics, with multiple approvals solidifying antisense oligonucleotide (ASO) and siRNA therapies as established treatment platforms. Ionis Pharmaceut... -
LNP-Delivered Multi-Specific CAR mRNA Engineering Platform Advances: Enables Controllable In Vivo CAR Expression, Overcomes Autologous Cell Manufacturing Challenges
Ace Therapeutics Unknown Overview A lipid nanoparticle (LNP)-formulated messenger RNA (mRNA) therapy platform is advancing as a novel strategy to generate CAR-expressing immune cells in vivo. This approach allows for transient and contro... -
Ribo Life Science’s siRNA Therapy Vortosiran Receives EMA Approval for Stroke Prevention Trial in Atrial Fibrillation Patients
Insight, China's Pharmaceutical Industry China Overview Ribo Life Science's siRNA therapy, vortosiran (BD4059), has received clinical trial approval from the EMA for stroke prevention in atrial fibrillation (SPAF) patients. Vortosiran is... -
First Half 2026 Sees 24 New Small-Molecule Approvals: Pioneering PROTAC Vepdegestrant and Oral GLP-1 Orforglipron Enter Market
Chemexpress China Overview Twenty-four small-molecule drugs received their first global approval in the first half of 2026, with 95.8% being oral dosage forms. Key highlights include the approval of the first commercial PROTAC, vepdegest... -
Daiichi Sankyo & AstraZeneca’s Enhertu Plus Pertuzumab Recommended for EU Approval as 1st-Line Treatment for HER2-Positive Metastatic Breast Cancer, Achieves 44% Risk Reduction in Phase III
Daiichi Sankyo Press Release Japan Overview The EMA's CHMP has recommended Enhertu (trastuzumab deruxtecan) in combination with pertuzumab for approval as a first-line treatment for HER2-positive metastatic breast cancer in the EU. This ... -
Insilico Medicine’s AI-Driven Pan-TEAD Inhibitor ISM6331 Receives FDA Fast Track Designation for Advanced Mesothelioma, Accelerating Development
Insilico Medicine Press Release USA Overview Insilico Medicine announced that its AI-driven pan-TEAD inhibitor, ISM6331, developed using the Chemistry42 platform, received Fast Track Designation from the FDA for advanced malignant pleura...
